The following "How I Treat" sessions on lymphoma will take place at the 2018 ASH Meeting on Hematologic Malignancies. View the full schedule and program.
How I Treat Hodgkin Lymphoma Patients
Nancy L. Bartlett, MD, Washington University School of Medicine in St. Louis
Nancy L. Bartlett, MD, is a professor of medicine and the Koman Endowed Chair in Medical Oncology at the Siteman Cancer Center at Washington University in St. Louis. She is a co-chair of the Alliance Cooperative Group Lymphoma Committee and serves on the Alliance Board of Directors.
Dr. Bartlett’s research interests include clinical trials in both non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL). She is currently involved in the design and/or conduct of multiple trials of brentuximab vedotin in HL and diffuse large B-cell lymphoma (DLBCL); interim PET studies in HL and NHL; ibrutinib studies in follicular lymphoma, DLBCL, and mantle cell lymphoma; CAR T-cell therapy in DLBCL; CD20 bi-specific antibody in NHL; and novel immunotherapy approaches to both NHL and HL.back to top
How I Treat Mantle Cell Lymphoma
In this session, Dr. Kristie Blum will provide a review of an individualized approach to the treatment of patients with newly diagnosed mantle cell lymphoma, focusing on age as well as specific clinical and biologic characteristics of the disease. Ongoing areas of research, including active clinic trials and trials in development, will also be presented.
Kristie Blum, MD, Emory University
Kristie A. Blum, MD, is acting professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. A board-certified hematologist, she has extensive experience in the clinical development of novel therapeutics for patients with aggressive B-cell non-Hodgkin lymphoma and Hodgkin lymphoma. Prior to joining Emory in 2017, Dr. Blum was a professor in the Division of Hematology at The Ohio State University James Cancer Hospital and Solove Research Institute, where she was also the director of the Lymphoma Clinical Research Program.
Dr. Blum is a co-chair of the NCI Lymphoma Steering Committee. She is also a member of the Lymphoma Research Foundation Scientific Advisory Board, the Alliance Cooperative Group Lymphoma Committee, the American Society of Hematology Clinical Research Mentoring Program, and the National Comprehensive Cancer Network Hodgkin Lymphoma Panel. Dr. Blum developed and chaired the first two Lymphoma Research Foundation Clinical Research Mentoring Programs from 2013 to 2015.back to top
When Do I Treat Aggressive Lymphoma Patients With Something Other Than R-CHOP?
Jonathan W. Friedberg, MD, University of Rochester
Jonathan W. Friedberg, MD, is the Samuel Durand Professor of Medicine at the University of Rochester and director of the James P. Wilmot Cancer Institute. He received his medical degree from Harvard Medical School and did his postgraduate training at Massachusetts General Hospital. Dr. Friedberg completed a medical oncology and hematology fellowship at Dana-Farber/Partners Cancer Care in Boston. He has a Master of Medical Sciences in Clinical Investigation from Harvard Medical School.
Dr. Friedberg’s research interests focus on development of novel therapies for patients with lymphoma. He is chair of the lymphoma committee in the SWOG NCTN group and serves as associate editor for hematologic malignancies at Journal of Clinical Oncology. Dr. Friedberg was awarded the Scholar in Clinical Research award from the Leukemia and Lymphoma Society. He has chaired the Education Program of the American Society of Hematology annual meeting.back to top
How I Treat Follicular Lymphoma
John Leonard, MD, Weill Cornell Medical College
John P. Leonard, MD, is the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology and associate dean for clinical research at the Weill Cornell Medical College. He is vice chairman for clinical research of the Department of Medicine and associate director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College and New York Presbyterian Hospital where he also serves as an attending physician, chief of the lymphoma service, and director of the Joint Clinical Trials Office. Dr. Leonard is chair of the Lymphoma Committee of the Alliance for Clinical Trials in Oncology (formerly CALGB, ACOSOG, and NCCTG) of the National Cancer Institute’s National Clinical Trials Network. He is chair of the Scientific Advisory Board and a board member of the Lymphoma Research Foundation and of the Leukemia and Lymphoma Society/New York City Chapter.
Dr. Leonard’s primary research interest is in the development of novel therapeutic strategies for the treatment of lymphoma and related hematologic malignancies. Much of his work has involved the development of novel therapies for lymphoma, including monoclonal antibodies, other immune-based treatments, targeted agents, and other innovative approaches. Dr. Leonard has also studied prognostic, imaging, and survivorship issues for lymphoma patients.back to top
How Should I Refer Patients With Lymphoma for AlloSCT and CAR T-Cell Therapy?
Stephen J. Schuster, MD, University of Pennsylvania
back to top